272 related articles for article (PubMed ID: 19200858)
1. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T
J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
[TBL] [Abstract][Full Text] [Related]
2. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
3. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
4. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow up of glatiramer acetate compassionate use in Belgium.
Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
[TBL] [Abstract][Full Text] [Related]
6. New options for early treatment of multiple sclerosis.
Tintoré M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
[TBL] [Abstract][Full Text] [Related]
7. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of glatiramer acetate in clinical practice: an observational study.
Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
[TBL] [Abstract][Full Text] [Related]
9. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
Rovaris M; Comi G; Filippi M
J Neurol Sci; 2005 Jun; 233(1-2):139-43. PubMed ID: 15949501
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy.
Zvartau-Hind M; Caon C; Zabad R; Tselis A; Lisak R; Khan O
Expert Rev Neurother; 2002 May; 2(3):285-94. PubMed ID: 19810859
[TBL] [Abstract][Full Text] [Related]
11. What can be learned from open direct comparative trials in multiple sclerosis?
Khan O
J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Johnson KP
Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
Karussis D; Teitelbaum D; Sicsic C; Brenner T;
J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer in the treatment of multiple sclerosis.
Rizvi SA; Kim E; Moodie J
Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate in multiple sclerosis.
Mezzapesa DM; Rovaris M; Filippi M
Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
[TBL] [Abstract][Full Text] [Related]
20. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
